Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Feb 15:2021:8867985.
doi: 10.1155/2021/8867985. eCollection 2021.

Plateletcrit and Mean Platelet Volume in the Evaluation of Alcoholic Liver Cirrhosis and Nonalcoholic Fatty Liver Disease Patients

Agata Michalak  1 , Halina Cichoż-Lach  1 , Małgorzata Guz  2 , Joanna Kozicka  1 , Marek Cybulski  2 , Witold Jeleniewicz  2
Affiliations
Clinical Trial

Plateletcrit and Mean Platelet Volume in the Evaluation of Alcoholic Liver Cirrhosis and Nonalcoholic Fatty Liver Disease Patients

Agata Michalak et al. Biomed Res Int. .

Abstract

Platelet (PLT) indices have been proposed as potential markers in the assessment of liver fibrosis and exacerbation of liver failure. The aim of our study was to verify mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in alcohol-related liver cirrhosis (ALC) and nonalcoholic fatty liver disease (NAFLD) patients. One hundred forty-two patients with ALC, 92 with NAFLD, and 68 in control group were enrolled in this study. Hematological indices (MPV, PCT, and PDW) and serological (indirect and direct) markers of liver fibrosis (AAR, APRI, FIB-4, GPR, PICP, PIIINP, TGF-α, PDGF-AB, laminin) were measured in each participant. MELD score in ALC patients and NAFLD fibrosis score (NFS) together with BARD score in the NAFLD group were also obtained. Results were compared between research and control groups. Then, a correlation between evaluated indices was performed in study groups. Receiver operating characteristic curves (ROCs) and area under the curve (AUC) values were applied to assess the diagnostic accuracy of measured indices. Significant increase in PDW and decrease in PCT in comparison to controls were noted in examined ALC (60.4% vs. 51.2% and 0.1% vs. 0.21%, respectively, p < 0.0001) and NAFLD (54.75% vs. 51.2% and 0.19 vs. 0.21%, respectively, p < 0.01) patients. Decreased level of MPV was observed in NAFLD group (7.85 fl vs. 8.90 fl, p < 0.0001). Additionally, PCT correlated with NFS (p < 0.0001). Evaluated PLT indices correlated with MELD score (MPV and PDW, p < 0.001; PCT, p < 0.05). They correlated with indirect and direct markers of liver fibrosis in the whole research group, too. PCT was the parameter with the greatest diagnostic accuracy in ALC patients (AUC = 0,839 for cutoff < 0.17%); in NAFLD group, it was MPV (AUC = 0,808 for cutoff < 7.9 fl). PCT in ALC and MPV in NAFLD can be perceived as potential diagnostic markers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Flow chart displaying the selection of study participants. ALC: alcohol-related liver cirrhosis; NAFLD: nonalcoholic fatty liver disease; US: ultrasound.
Figure 2
Figure 2
ROCs for assessed markers in observed patients: (a) MPV in the ALC group; (b) PDW in the ALC group; (c) PCT in the ALC group; (d) MPV in the NAFLD group; (e) PDW in the NAFLD group; (f) PCT in the NAFLD group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lackner C., Tiniakos D. Fibrosis and alcohol-related liver disease. Journal of Hepatology. 2019;70(2):294–304. doi: 10.1016/j.jhep.2018.12.003. - DOI - PubMed
    1. Sookoian S., Pirola C. J. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside. Alimentary Pharmacology & Therapeutics. 2019;49(5):516–527. doi: 10.1111/apt.15163. - DOI - PubMed
    1. Grgurevic I., Podrug K., Mikolasevic I., Kukla M., Madir A., Tsochatzis E. A. Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Canadian Journal of Gastroenterology & Hepatology. 2020;2020, article 9181368:10. doi: 10.1155/2020/9181368. - DOI - PMC - PubMed
    1. Gustot T., Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease. Journal of Hepatology. 2019;70(2):319–327. doi: 10.1016/j.jhep.2018.12.008. - DOI - PubMed
    1. Moreno C., Mueller S., Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Journal of Hepatology. 2019;70(2):273–283. doi: 10.1016/j.jhep.2018.11.025. - DOI - PubMed

Publication types

LinkOut - more resources